NCT05813678
Phenylketonuria, Phenylketonuria (PKU)
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment (incident-users) or have previously started treatment with pegvaliase at the date of enrollment (prevalent-users) are eligible for participation in this study.
All
Any
No
Pegvaliase
Observational
450
2022-06-06
2024-05-13
Aurora, Colorado, United States
Trial Status Recruiting
Chicago, Illinois, United States
Trial Status Recruiting
Indianapolis, Indiana, United States
Trial Status Recruiting
New Orleans, Louisiana, United States
Trial Status Recruiting
Portland, Oregon, United States
Trial Status Recruiting
Pittsburgh, Pennsylvania, United States
Trial Status Recruiting
Dallas, Texas, United States
Trial Status Recruiting
Milwaukee, Wisconsin, United States
Trial Status Recruiting
Cottbus, Germany
Trial Status Recruiting
Hamburg, Germany
Trial Status Recruiting
Münster, Germany
Trial Status Recruiting
Ulm, Germany
Trial Status Recruiting
Bologna, Italy
Trial Status Recruiting
Florence, Italy
Trial Status Recruiting
Milan, Italy
Trial Status Recruiting
Naples, Italy
Trial Status Recruiting
*required fields
"*" indicates required fields